Clinical trials: Semaglutide, completed
Diabetes Mellitus, Type 2
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease.
- Trial name
- SOUL (NCT03914326)
- Testing
- Semaglutide
- Where
- 492 sites in United States, Algeria and 32 more
- Volunteers
- 9,651 people
- Sponsor
- Novo Nordisk A/S
Obesity, Childhood
Lifestyle Counseling and Medication for Adolescent Weight Management
The prevalence of adolescent severe obesity is at an all-time high in the United States and the refractory nature of this disease has led to a serious and challenging conundrum in terms of how to provide effective, safe…
- Trial name
- QUEST (NCT04873245)
- Testing
- Intensive Behavioral Program, Semaglutide and Behavioral Program
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Minnesota
PCOS, Adolescent Obesity
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat…
- Conditions
- PCOS, Adolescent Obesity, NAFLD
- Trial name
- TEAL (NCT03919929)
- Testing
- Semaglutide 3mg and 7mg [Rybelsus], Weight loss diet
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
Overweight, Obesity
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World
This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide…
- Conditions
- Overweight, Obesity, Atherosclerotic Cardiovascular Disease (ASCVD)
- Trial name
- SCORE (NCT06874751)
- Testing
- No treatment given
- Where
- United States
- Volunteers
- 45,456 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Coronary Artery Disease
Semaglutide Treatment On Coronary Progression
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis.
- Trial name
- STOP (NCT03985384)
- Testing
- Semaglutide 2 MG/1.5 ML Subcutaneous Solution
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Diabetes, Diabetes Mellitus, Type 2
Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is event-driven, i.e.
- Trial name
- SUSTAIN™ 6 (NCT01720446)
- Testing
- semaglutide
- Where
- 253 sites in United States, Algeria and 19 more
- Volunteers
- 3,297 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss
This observational study is designed to determine the feasibility of recruitment from a digital research community of people using an anti-obesity medication for weight loss to understand willingness to consent to survey research…
- Trial name
- COSMOS-DIGITAL (NCT06761703)
- Testing
- TAP® Micro Select Device (Touch Activated Phlebotomy)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Amgen
Diabetes Mellitus, Type 2
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
In this study, participants will receive semaglutide and NNC0480-0389 together at the same time. Semaglutide is a medicine that can already be prescribed, whereas NNC0480-0389 is a new potential medicine.
- Trial name
- NCT05046873
- Testing
- Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL, Semaglutide 1.34 mg/mL, NNC0480-0389 A 10 mg/mL
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Pulmonary Embolism
Semaglutide Use in Acute Pulmonary Embolism
Evaluation of circulating endothelial inflammatory biomarkers in response to GLP-1 agonist Semaglutide in acute pulmonary embolism
- Trial name
- NCT06118203
- Testing
- Semaglutide
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Imperial College London
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
- Trial name
- NCT02453711
- Testing
- semaglutide, liraglutide
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 957 people
- Sponsor
- Novo Nordisk A/S
Alcohol-related Liver Disease
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease.
- Trial name
- NCT06409130
- Testing
- NNC0194-0499, Semaglutide, Cagrilintide + semaglutide
- Where
- 102 sites in United States, Australia and 12 more
- Volunteers
- 270 people
- Sponsor
- Novo Nordisk A/S
Weight Loss
Effect of a Low-carbohydrate Diet on Weight Loss in People Using the Injectable GLP-1 Agonist Semaglutide for Weight Loss
The goal of this clinical trial is to determine the effect of a low carbohydrate higher protein diet, modelled after the Atkins program on weight loss, glycemic control, risk markers of cardiovascular disease and body composition…
- Trial name
- NCT07280403
- Testing
- Low Carbohydrate, Low Fat
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- INQUIS Clinical Research
Diabetes Mellitus, Type 2
O-SEMA-Fast: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Plan to Fast During Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait
The purpose of the study is to look at the change in blood sugar levels in people with type 2 diabetes who are using oral semaglutide and planning to fast during Ramadan.
- Trial name
- O-SEMA-Fast (NCT05716724)
- Testing
- Semaglutide
- Where
- 20 sites in Kuwait, Saudi Arabia and 1 more
- Volunteers
- 288 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04601753)
- Testing
- Oral Semaglutide
- Where
- Sweden
- Volunteers
- 194 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Healthy
A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects
This trial is conducted in Europe. Tha aim of this trial is to investigate the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in healthy subjects.
- Trial name
- NCT03010475
- Testing
- Furosemide, Rosuvastatin, SNAC
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity
This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 2 (NCT03552757)
- Testing
- Semaglutide 1.0 mg, Semaglutide 2.4 mg
- Where
- 147 sites in United States, Argentina and 11 more
- Volunteers
- 1,210 people
- Sponsor
- Novo Nordisk A/S
Non-alcoholic Steatohepatitis
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
- Trial name
- NCT05016882
- Testing
- NNC0194 0499 50 mg/mL, Semaglutide 3 mg/mL, NNC0174 0833 10 mg/mL
- Where
- 255 sites in United States, Australia and 22 more
- Volunteers
- 698 people
- Sponsor
- Novo Nordisk A/S
OSA
Study That Tests AD109 in Patients Taking GLP-1 Drugs
Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide
- Trial name
- NCT06400615
- Testing
- AD109
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Apnimed
Overweight, Obesity
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Part A: The study will look at participants appetite and energy intake and also look at the mechanisms of brain associated with appetite and food intake.
- Trial name
- NCT06267092
- Testing
- No treatment given, Cagrilintide and Semaglutide
- Where
- Germany
- Volunteers
- 164 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile.
- Trial name
- NCT05533632
- Testing
- Semaglutide
- Where
- 3 sites in Chile
- Volunteers
- 104 people
- Sponsor
- Novo Nordisk A/S